AI Company Offers Pricey, Sometimes Inaccurate Predictions for Treating Dogs' Lymphoma
-
When Cory Padilla's dog Copper was diagnosed with lymphoma, Padilla learned about ImpriMed, a company using AI to make personalized predictions for treating canine lymphoma.
-
ImpriMed analyzes live cancer cells to determine lymphoma subtypes, conduct cell analysis, and test drug sensitivity to rank anticancer drugs by likelihood of effectiveness.
-
The cost of ImpriMed's services can be prohibitively expensive for pet owners, ranging from $1000-$1500 for the drug ranking predictions.
-
Some pet owners have had mixed experiences with ImpriMed's predictions, finding the top recommended drugs were not well tolerated by their dogs.
-
Experts say AI prediction models can be useful but should not replace the expertise of veterinary oncologists in determining the best clinical approach.